Germany’s Evonik to sell methacrylates business to US Advent for €3bn

Tracy Dang

04-Mar-2019

HOUSTON (ICIS)–Evonik has agreed to sell its methacrylates business to US-based private equity firm Advent International for €3bn, the Germany-based specialty chemicals company announced on Monday.

Expected to close in the third quarter, the transaction includes the Methacrylates, Acrylic Products and CyPlus business lines, as well as some methacrylate resins activities.

“Evonik put these operations on the market as part of its systematic strategy of sharpening its focus on specialty chemicals, which are less cyclical,” the producer said.

Evonik said in March 2018 that it was exploring options for its methacrylates business, including the possibility of divesting.

The methacrylates business has 18 production sites and 3,900 employees worldwide. It generated an average annual earnings before interest, taxes, depreciation and amortisation (EBITDA) of about €350m and sales of about €1.8bn/year in 2016-2018 and expects similar levels for 2019.

Evonik will use some sale proceeds for growth projects, including funding the acquisition of US-based PeroxyChem, which is expected to close this year. It will also use some funds to strengthen its specialty chemicals portfolio, including building a new polyamide 12 plant in Marl, Germany.

Follow Tracy Dang on Twitter

READ MORE

Global News + ICIS Chemical Business (ICB)

See the full picture, with unlimited access to ICIS chemicals news across all markets and regions, plus ICB, the industry-leading magazine for the chemicals industry.

Contact us

Now, more than ever, dynamic insights are key to navigating complex, volatile commodity markets. Access to expert insights on the latest industry developments and tracking market changes are vital in making sustainable business decisions.

Want to learn about how we can work together to bring you actionable insight and support your business decisions?

Need Help?

Need Help?